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Acute infection with hepatitis C virus (HCV) rarely is identified, and hence, the determinants 
of spontaneous resolution versus chronicity remain incompletely understood. In particular, 
because of the retrospective nature and unknown source of infection in most human studies, 
direct evidence for emergence of escape mutations in immunodominant major histocompatibility 
complex class I–restricted epitopes leading to immune evasion is extremely limited. In two 
patients infected accidentally with an identical HCV strain but who developed divergent 
outcomes, the total lack of HCV-specific CD4
 
 
 
 T cells in conjunction with vigorous CD8
 
  
 
T cells that targeted a single epitope in one patient was associated with mutational escape 
and viral persistence. Statistical evidence for positive Darwinian selective pressure against 
an immunodominant epitope is presented. Wild-type cytotoxic T lymphocytes persisted even 
after the cognate antigen was no longer present.
 
Chronic hepatitis C virus (HCV) infection is
common and affects 3% of the world’s popula-
tion; however, the diagnosis of acute HCV
rarely is made and usually is inferred based on
the history of a known exposure (1, 2).
Emerging data suggest that immunologic and
virologic events in the early stages of infection
determine the eventual outcome (3). Sponta-
neous resolution of acute HCV infection has
been associated with robust T cell responses in
chimpanzees (4, 5) and humans (6–8), and it
has been suggested that a threshold frequency
of CTL is required for clearance of HCV (9).
Although emergence of escape mutations in
class I MHC–restricted epitopes was shown
to lead to immune evasion in HCV-infected
chimpanzees (10, 11), direct evidence for this
mechanism in humans is limited. Tsai et al.
(12), by focusing on a single HLA A2–restricted
HCV E1 epitope in the hypervariable region,
observed variant epitope sequences with CTL
antagonist activity 3 mo from onset of acute
hepatitis in two patients who developed persis-
tence. Timm et al. (13) recently described the
development of CTL responses against an
HLA-B8–restricted epitope (including one
patient after antiviral therapy); however, mu-
tations within this immunodominant epitope
did not impact HLA class I binding or TCR
recognition.
We comprehensively studied two patients
who developed homologous acute HCV in-
fection after patellar tendon transplantation
from a deceased donor who was in the “win-
dow” phase of acute HCV (i.e., negative for
HCV antibody but positive for HCV RNA).
Antigenic and viral genetic mapping revealed
striking differences in these two individuals
who shared several HLA alleles but had diver-
gent outcomes. To assess the total and specific
CD4
 
 
 
 and CD8
 
 
 
 T cell response against all
potential HCV epitopes in an unbiased manner,
we used 750 overlapping 15-mer peptides that
spanned the entire HCV polyprotein. The lack
of HCV-specific CD4
 
 
 
 T cells, in conjunction
with vigorous CD8
 
 
 
 T cells that targeted a
single immunodominant epitope, was associ-
ated with mutational escape and viral persis-
tence. In contrast, the patient who demon-
strated vigorous and multispecific CD4
 
 
 
 and
CD8
 
 
 
 T cell responses spontaneously eradi-
cated HCV infection.
 
The online version of this article contains supplemental material.
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RESULTS AND DISCUSSION
Divergent outcomes after exposure to identical 
HCV-infected donor tissue
 
Two subjects with no previous history of exposure to HCV
underwent elective patellar ligament (with bone) transplan-
tation for knee reconstructive surgery in April 2002. Within
2 mo, both patients developed symptoms of fatigue and ele-
vation in liver function tests. The first patient (PD101, a 49-
yr-old white man) had elevation in his liver function tests
and persistent viremia, and was treated with pegylated inter-
feron and ribavirin. The second patient (PD102, a 51-yr-old
white woman) became jaundiced with a peak total serum
bilirubin of 8.1 mg/dl and spontaneously cleared HCV
RNA from serum within 3 mo. Their clinical and virologic
courses are shown in Fig. 1. Remarkably, both patients
shared several HLA alleles, including HLA A2.
 
HCV genome-wide analysis of CD4
 
 
 
 and CD8
 
 
 
T cell responses
 
To assess CD4
 
 
 
 and CD8
 
 
 
 T cell responses to the whole
HCV polyprotein comprehensively, 15 mer-peptides, over-
lapping by 11 amino acids, were pooled and used in an IFN-
 
 
 
ELISPOT assay. In brief, autologous dendritic cells were
used as APCs to stimulate bead-purified CD8
 
 
 
 T cells with
32 peptide pools that spanned subgenomic regions; the re-
maining “CD4
 
 
 
 others” were stimulated on the same day
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20042284/DC1).
Longitudinal direct ex vivo analysis of HCV-genome
wide CD4
 
 
 
 and CD8
 
 
 
 T cell responses revealed striking dif-
ferences after infection in the two individuals (Fig. 2). None
of the overlapping HCV peptides nor recombinant HCV
proteins (not depicted) elicited CD4
 
 
 
 T cell responses from
PD101; only one pool (NS3-5H, amino acids 1369–1479)
demonstrated significant CD8
 
 
 
 T cell responses 6 mo after
infection (Fig. 2 A). Conversely, PD102 demonstrated vig-
orous and multispecific CD4
 
 
 
 and CD8
 
 
 
 T cell responses
(Fig. 2 B). Therefore, these results were in accord with, and
extend, those reported in acute resolving HCV infection,
and demonstrated an association between a strong and broad
T cell response with recovery (6–8). 6 mo later, despite the
fact that serum HCV RNA remained negative during that
span, PD102 maintained vigorous HCV-specific CD4
 
 
 
 T
cell responses, with 40% of the polypeptide (13 of 32 peptide
pools) eliciting responses (Fig. 2 D). Because PD101 devel-
oped persistent viremia, he was treated with pegylated inter-
feron and ribavirin starting 9.5 mo after infection. The pa-
tient’s CD8
 
 
 
 T cells targeted determinants limited to the
NS3-5H pool throughout follow-up, including 24 mo after
infection (Fig. 2 E). Of the individual peptides that made up
the latter pool, only one 15-mer peptide (amino acids 1401–
1415) stimulated CD8
 
 
 
 T cell responses. Therefore, only
one of the 750 peptides screened elicited CD8
 
 
 
 T cell re-
sponses in PD101. Mapping identified peptide 1406–1415 as
the minimal epitope, previously reported to be detectable by
tetramer analysis in almost one third of HLA A2-positive,
HCV-exposed individuals (14).
Tetramer frequencies for this epitope ranged from 1.43%
(8 mo) to 2.24% (22 mo after infection; Table S1, available
at http://www.jem.org/cgi/content/full/jem.20042284/
DC1). Direct ex vivo phenotypic analysis of NS3 1406 tet-
ramer-positive cells revealed intermediate memory cells,
consistently high expression of the costimulatory molecule
CD28, and decreasing levels of HLA-DR after viral clear-
ance with therapy. Over time, CCR7 expression increased,
which indicated the presence of early (central)—rather than
mature—effector memory CTLs (reference 15 and Fig.
S2, available at http://www.jem.org/cgi/content/full/jem.
20042284/DC1). To investigate the proliferative capacity of
these NS4 1406–specific CD8
 
 
 
 T cells at the single cell
level, PBMCs were cultured short-term with HCV peptides
and low-dose IL-2 and stained with carboxyfluorescein suc-
cinimidyl ester (CFSE), as described previously (14). As shown
in Fig. 3, PD101 demonstrated a strikingly high frequency of
proliferating NS3 1406 tetramer
 
 
 
 cells.
 
Evidence for immune escape of a single dominant epitope
 
Sequencing of a contiguous region encoding the NS3-5H
pool revealed an amino acid substitution at amino acid posi-
Figure 1. HCV infection in two subjects who were exposed acci-
dentally on the same day to HCV genotype 1a–infected patellar 
tendon that resulted in divergent outcomes. PD101 (top) developed 
elevation in serum alanine aminotransferase (ALT) and HCV RNA viremia 
that persisted until initiation of antiviral therapy with pegylated interferon 
and ribavirin. PD102 developed marked elevations in serum alanine ami-
notransferase and bilirubin; viremia became undetectable spontaneously 
without antiviral therapy. 
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tion 4 of the epitope (A
 
→
 
V) at 4.5, 6, 8, and 10 mo after in-
fection in PD101 (Fig. 4 A). Sequencing of the dominant vi-
rus from the donor and PD102 at 6 wk after infection
revealed identity with the prototype sequence; this indicated
that the alanine to valine change in PD101 represented a new
mutation that arose after transmission from the donor organ.
This de novo nonsynonymous mutation was propagated sta-
bly until antiviral therapy was initiated and was compatible
with virus replication; serum viral load increased between the
third and sixth month after infection (Fig. 1). Therefore, in
accord with a recent HIV model, one could speculate that
this rapidly emerging viral variant likely faced a low “genetic
barrier” (requiring only one or a few nucleotide changes) that
carried a low fitness cost to replication (16).
To determine if escape from T cell surveillance and
chronic infection might have resulted from a mutation in
this immunodominant NS3 1406 epitope, the mutant pep-
tide was loaded on autologous DCs, and CD8
 
 
 
 T cell re-
sponses were tested directly ex vivo in an ELISPOT assay.
As shown in Fig. 4 B, the mutant epitope failed to elicit
IFN-
 
 
 
 CD8
 
 
 
 T cell responses; this supported the concept
that virus variation which evolved in vivo outstripped the
capacity of T cells to control the infection (i.e., circulating T
cells did not react to the infecting sequence). Furthermore,
Figure 2. HCV–genome-wide analysis of CD4  and CD8  T cell 
responses in PD101 and PD102 at 6, 12, and 24 mo after infection. 
Overlapping 15 mer-peptides (n   750) were synthesized to span the 
complete HCV polyprotein derived from HCV-1a (the sequence data are 
available from GenBank/EMBL/DDBJ under accession no. M62321) and 
divided into 32 peptide pools. IFN-  production was detected using an 
established ELISPOT protocol. CD8  cells were isolated from PBMCs by 
magnetic-activated cell sorting magnetic bead separation (Miltenyi Bio-
tec) and the remaining CD4  others were used. Negative controls in the 
ELISPOT assay were wells with purified T cells but no peptide (n   8). After 
plates were dry, spots were quantified by a Zeiss microscope using KS 
ELISPOT software. Responses were considered positive if greater than the 
mean plus three SD of the control wells (DMSO only), if there were at least 
10 spots above background, and/or were significant by Student’s t test 
(P   0.05). Shown are the mean   SEM. (A and B) CD4  and CD8  T cell 
responses for PD101 and PD102 at 6 mo after infection. The difference in 
total immune response to the HCV peptides between patients was statisti-
cally significant (P   0.0005, Fisher’s two-tail test). (C and D) CD4  and 
CD8  T cell responses for PD101 and PD102 at 12 mo after infection. 
(E and F) T cell responses for PD101 and PD102 at 24 mo after infection. 
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because peptide variants of class I–restricted epitopes poten-
tially could antagonize naturally occurring epitopes (17), we
explored this possibility by using different ratios of wild-type
and mutant peptide concentrations. Mutant peptide did not
inhibit IFN-
 
 
 
 production after stimulation with the wild-
type peptide (Fig. 4 B). These results may be due to the fact
that the variant peptide bound to the HLA-A2 molecule
with decreased affinity (Fig. 4 C).
To assess whether the emergence of the viral variant was
the result of genetic drift or selective immune pressure, nu-
cleotide sequences that contained the first 2741 codons of
the polyprotein open reading frame were determined for the
dominant quasispecies for the donor, PD101, and PD102 by
directly sequencing the RT-PCR products. First, the ho-
mology between the amino acid sequence for PD101 and
the peptides that we synthesized was 96.64%; thus, the pep-
tides that were used to screen responses closely matched the
infecting virus (Fig. 5). Second, the sequences from PD101
and PD102 differed by only 11 nucleotides in the open
reading frame (99.9% identity) and led to 8 amino acid
differences (99.7% identity). Third, the nucleotide se-
quences for the donor and PD102 were identical except
Figure 3. Proliferation of HCV-specific tetramer  CD8  T cells. On 
day 8 of culture in HCV peptide–stimulated T cell lines derived from 
PD101 and PD102, CFSE-labeled tetramer  cells were detected. In 
brief, 107 PBMCs were cultured in the presence of four HCV epitope pep-
tides (NS3 1406–1415 [KLVALGINAV], NS3 1073–1081 [CINGVWCTV], and 
core 132–140 [DLMGYIPLV]) with IL-2 (0.5 ng/ml) added on days 0 and 3. 
Because the CFSE signal is diluted with each cell division, signals in the left 
upper quadrant represent viral-specific CD8  T cells that have proliferated 
in culture. Those in right upper quadrant represent tetramer  T cells that 
have not divided (reference 14). (A) In PD101, the NS3 1406–specific CD8  
T cells expanded after peptide stimulation (representing 29% of gated 
CD8  T cells) and NS3 1073–specific CD8  T cells demonstrated modest 
proliferation, whereas the other epitope tetramer  cells were viable but 
failed to expand, as indicated by the tetramer  cells in the upper right 
quadrants of the dot plots. Analysis from two other time points after 
infection revealed similar results. (B) For PD102, in vitro culture for 8 d led 
to proliferation of NS3 1406– and NS3 1073–specific CDD8  T cell 
responses. In contrast, neither core-specific nor NS5B 2594–specific 
responses expanded in culture. Analysis from two other time points 
revealed similar results. Figure 4. Mutant viral sequence, recognition, and binding of 
mutant peptide. (A) Viral sequences corresponding to the single peptide 
that elicited CD8  T cells from PD101 who developed viral persistence. The 
prototype HCV-1 peptide sequence is shown; dashes indicate identity with 
the prototype and substitutions are represented by standard letter codes 
at different time points after infection. The donor sequence is identical to 
the prototype sequence and the sequence derived from PD102 who spon-
taneously cleared HCV RNA. In contrast, PD101 developed a mutation 
within the NS3 1406–1415 epitope (A1409V) by 4.5 mo after infection 
that was propagated until antiviral therapy was initiated. (B) CD8  T cells 
from PD101 (from 8 mo after infection) recognize wild-type NS3 1406 
peptide, but not mutant 1406 peptide. Dose titrations of wild-type, 
mutant, and combination of both peptides reveal high frequency of IFN- –
producing effector cells after pulsing of autologous DCs with wild-type 
peptide and culture with bead-purified CD8  T cells without antagonism 
by the mutant peptide. Wild-type and nonwild-type peptides were 
screened at multiple concentrations. (C) MHC class I binding affinity. 
Transporter associtated with antigen-processing–deficient T2 cells (105) 
were cultured for 16 h at 26 C to increase expression of peptide-receptive 
cell surface molecules, and then were incubated with various concentra-
tions of individual peptides (wild-type NS3 1406, mutant NS3 1406, or 
DMSO) at 37 C for 1 h, washed, and stained with FITC-labeled anti–HLA-
A2 antibody (BD Biosciences), as described previously (24). The variant 
peptide bound to the HLA-A2 with decreased affinity (P   0.0014), 
comparable to DMSO (no peptide) control. Data are expressed as the mean 
fluorescence intensity. 
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for 1 nucleotide in the 5
 
 
 
UTR; their polyproteins from
amino acid 1–2741 were identical. The amino acid differ-
ences between the sequences were (donor/PD102:PD101):
F399L, A937V, V1384A, A1409V, T1474I, A2169T,
P2341S, and D2597E. As shown in Fig. 5
 
 
 
B, these nonsyn-
onymous mutations occurred throughout the HCV genome,
including two HLA-A2–restricted epitopes. Therefore, in
PD101, the rate of amino acid substitution within the im-
munodominant NS3 1406 CTL epitope (the only peptide
that elicited CD8 responses) was 1 of 10 amino acids (10%)
versus 4 of 2731 (0.15%) in the remaining flanking or non-
HLA-A2–restricted regions. An exact Fisher test indicates
that the number of substitutions is not independent of the
amino acid position (P 
 
 
 
 0.018). These data support a role
for CD8
 
 
 
 T cell selective pressure as the cause of amino acid
substitution because it is unlikely that this mutation arose
randomly in this epitope.
The other HLA A2–restricted epitope (NS5B) demon-
strated an amino acid substitution in PD101 (D2597E) that
was not present in the donor or PD102. Specific stimulation
with this mutant peptide (D2597E, T2600S), prototype 1a,
and donor (T2600S) peptide demonstrated proliferation to
the peptide derived from the initial infecting sequence
(T2600S), but not the mutant peptide (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20042284/DC1).
Reports of individuals who were exposed to a single
source HCV infection have been limited to subjects who ac-
quired the infection in the remote past (18), and conse-
quently, immunologic and virologic analyses were per-
formed long after the outcome of infection was determined.
In this study, we prospectively tracked two patients early af-
ter they acquired HCV infection from the same acutely in-
fected, “window period” donor. Comprehensive mapping
of CD4
 
 
 
 and CD8
 
 
 
 T cell responses with overlapping 15
mer-peptides spanning the entire HCV polyprotein revealed
statistically significant differences in the breadth and vigor of
T cell responses between both individuals. These results are
even more compelling when one considers that the autolo-
gous, infecting viral sequences and the peptides that were
used to screen responses were nearly identical (presumably
facilitating immune recognition), and that the subjects shared
several HLA alleles, including the highly prevalent HLA A2
(also present in the donor).
Our results are consistent with the concept that the vari-
ant HCV carrying a substitution within an immunodomi-
nant CD8
 
 
 
 T cell epitope was selected by the monospecific
antiviral CTL response, and the variant epitope (perhaps be-
cause of lack of HCV-specific CD4
 
 
 
 T cell help [11]) failed
 
Figure 5. Comparison of viral genetic sequence of donor, PD101, 
and PD102. 
 
(A) Dendrogram showing genetic relatedness of donor, 
PD101, and PD102 relative to other HCV isolates. Donor, PD101 (the se-
quence data are available from GenBank/EMBL/DDBJ under accession no. 
AY695436), and PD102 PD102 (the sequence data are available from Gen-
Bank/EMBL/DDBJ under accession no. AY695437) amino acid sequences 
were aligned against the corresponding sequences from the reference 1a 
isolate from which the peptides were derived (M62321), and a genotype 
1b isolate (J4). The length of the horizontal lines connecting two isolates 
by the shortest route (right to left and left to right) is proportional to the 
genetic distance between the isolates. (B) Viral sequences for the proto-
type HCV-1 peptide sequence, donor, PD101 (6 mo after infection), and 
PD102 (1.5 mo) are shown; dashes indicate identity with the prototype 
and substitutions are represented by standard letter codes at different 
time points after infection. Known class I restricted epitopes are indicated 
in brackets [HLA A2 and B35]. 
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to generate new variant-specific CTL populations. The only
peptide region that elicited IFN-
 
 
 
 response in PD101 was
the class I–restricted epitope region where a nonsynonymous
mutation arose and was maintained. In contrast, the likeli-
hood of CTL escape is low when the CTL response is di-
rected against multiple viral epitopes simultaneously, as in
the case of PD102. We acknowledge the possibility that T
cell responses were broader at time points earlier than the 6
mo when samples first became available.
One of the most striking findings in our study was that
the CTL effector response (IFN-
 
 
 
 production and prolifera-
tive capacity) in PD101 was maintained even when the cog-
nate antigen that it recognizes was no longer present (after
viral escape and after therapeutic viral eradication). This ap-
parent paradox was described previously in a human study of
HBV infection (19) and in HCV-infected chimpanzees (9);
it could be related to recurrent stimulation from an unde-
fined reservoir of wild-type virus (20), as suggested by the
recent demonstration of low-level HCV replication in PB-
MCs of patients with therapy-induced or spontaneous reso-
lution of HCV infection (20). Alternatively, mutant epitopes
could stimulate expansion of the wild-type–specific CTL—a
phenomenon known as “original antigenic sin”—that ini-
tially was described for antibodies, but also extended to class
I HLA-restricted responses (9, 21). Direct enumeration of
the frequency of mutant-specific CTL with tetramers was
not possible because attempts to synthesize them failed on
two occasions, possibly a reflection of the fact the mutant
peptide bound to the HLA-A2 molecule with lower affinity
than the wild-type peptide (which also might explain the
lack of antagonistic activity of the mutant peptide; Fig. 4 B).
In summary, our findings—derived by combining viral
sequence data and unbiased, functional T cell analyses that
examine every potential HCV epitope after homologous
challenge—indicate that the absence of CD4
 
 
 
 T cell help,
coupled with strong selective pressure exerted by wild-type–
specific CTLs, favor the emergence of immune escape (11)
and indicate a patient profile associated with chronicity that
might benefit from early antiviral therapy. Elucidation of the
mechanisms which underlie the early failure to develop
HCV-specific CD4
 
 
 
 T cells and their instructive signals dur-
ing memory CD8
 
 
 
 T cell differentiation has implications for
vaccine strategies that are designed to induce protective im-
munity to this common disease (22).
 
MATERIALS AND METHODS
 
The study protocol was approved by the Human Research Committee and
Institutional Review Board of Oregon Health and Science University.
 
Synthetic peptides.
 
A total of 750 overlapping (15-mers) peptides span-
ning the entire polyprotein (Fig. S1) of HCV-1a (accession no. M62321)
was synthesized at NMI Laboratories.
 
ELISPOT assay.
 
IFN-
 
 
 
 production was detected using an established
ELISPOT protocol (23).
 
Flow cytometry.
 
Flow cytometric analysis using a fluorescence activated
cells sorter FACSCalibur (Becton Dickinson) was performed on the CD8
 
 
 
T cell population to determine purity and on the CD4
 
 
 
 others to determine
the percentage of CD3
 
 
 
CD4
 
 
 
 T cells in the population. Data analysis was
performed using CellQuest and FlowJo software. Fluorescent-conjugated
anti–human antibodies for T cell subsets, activation, memory, and differen-
tiation markers (BD Biosciences and Caltag) were used. Soluble HLA-A2
tetramers containing core amino acids 132–140 (DLMGYIPLV), NS3
1073–1081 (CINGVWCTV), NS3 1406–1415 (KLVALGINAV), and NS5
2594–2602 (ALYDVVTKL) were synthesized (Beckman Coulter and NI-
AID tetramer facility) and used to screen responses longitudinally.
 
In vitro proliferation of CFSE-labeled T cells.
 
10
 
7
 
 cells were stained
in 0.1% BSA in PBS with 1 
 
 
 
M CFSE (Molecular Probes); PBMCs were
cultured with 10 
 
 
 
g/ml each of Core 131, NS3 1073, NS3 1406, and NS5
2594 epitope peptides and 0.5 ng/ml IL-2 (on days 0 and 3).
 
Isolation, amplification, and sequencing of HCV genomes.
 
The
plasma of both patients were collected by centrifugation in plasma prepara-
tion tubes and frozen immediately at 
 
 
 
80
 
 
 
C. RNA was isolated with the
QIAamp Viral RNA Mini Kit (QIAGEN) according to the manufacturer’s
instructions. The RNA was reverse transcribed using random oligonucle-
otide primers and M-MLV Reverse Transcriptase (Fisher Scientific) for 60
min at 37
 
 
 
C. HCV sequences, including nt 93–8566 (reference sequence
AF009606), were amplified using nested RT-PCR in four overlapping seg-
ments using the primers and conditions that are described in Table S2
(available at http://www.jem.org/cgi/content/full/jem.20042284/DC1).
The sequence of the dominant quasispecies was obtained by sequencing
both strands of each amplicon directly using primers averaging 300 nt apart,
and the full sequence was assembled with the Vector NTI software package.
 
Statistical analysis.
 
Results were graphed and analyzed using GraphPad
Prism and JMP (SAS Institute) statistical package.
 
Online supplemental material.
 
Figs. S1–S3 and Tables S1 and S2 dem-
onstrate the whole genome sequencing and T cell mapping approach. Enu-
meration and phenotype of HCV-specific, HLA-A2 epitope responses and
proliferative responses after stimulation with wild-type and mutant peptides
are shown. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20042284/DC1.
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